Combination anti-VEGF and corticosteroid therapy for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome

Copyright 2013, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 44(2013), 6 vom: 01. Nov., Seite 599-602
1. Verfasser: Sawhney, Gagan K (VerfasserIn)
Weitere Verfasser: Payne, John F, Ray, Robin, Mehta, Sonia, Bergstrom, Chris S, Yeh, Steven
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Case Reports Journal Article Research Support, Non-U.S. Gov't Adrenal Cortex Hormones Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Bevacizumab 2S9ZZM9Q9V
Beschreibung
Zusammenfassung:Copyright 2013, SLACK Incorporated.
Vision loss associated with the idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome most commonly occurs from macular edema or complications related to neovascularization. The authors present a case of advanced IRVAN associated with a massive exudative response characterized by peripheral retinal telangiectasias, exudative retinal detachment, and macular edema with lipid maculopathy. The patient was managed successfully with visual acuity from hand motion to 20/150 using a combination of local corticosteroids, intravitreal bevacizumab, panretinal photocoagulation, and eventually pars plana vitrectomy for progressive vitreomacular traction. VEGF- and non-VEGF-mediated mechanisms appear to be involved in the pathogenesis of IRVAN given the efficacy of combination therapy. [ophthalmic surg lasers imaging retina. 2013;44:599-602.]
Beschreibung:Date Completed 05.05.2014
Date Revised 19.11.2015
published: Print
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20131105-09